Download full text in PDF

Gabli Z, Djerrou Z, Beddar L. Histopathological and immunohistochemical investigation of mammary tumors in female cats in Northeast Algeria. Bìol. Tvarin. 2023; 25 (3): 3–13.
https://doi.org/10.15407/animbiol26.03.003
Received 26.07.2024 ▪ Revision 23.09.2024 ▪ Accepted 25.09.2024 ▪ Published online 01.10.2024

Histopathological and immunohistochemical investigation of mammary tumors in female cats in Northeast Algeria

Zahra Gabli¹, Zouhir Djerrou¹, Leila Beddar²
This email address is being protected from spambots. You need JavaScript enabled to view it.

¹Natural and Life Sciences Department, Faculty of Sciences, University of August 20^th 1955, B.P.26 route d’El-Hadaiek, Skikda 21000, Algeria
²Ben Badis University Hospital Center, Constantine 25000, Algeria

Cancer is a leading cause of feline mortality globally. This study focuses on delineating mammary gland tumor prevalence and anatomopathological characteristics in cats from northeastern Algeria. Encompassing the period from January 2021 to March 2022, the research included 50 cats from Constantine and Annaba provinces, revealing an overall 20% feline mammary tumors (FMT) prevalence. Siamese cats exhibited a higher rate compared to crossbred cats, with a mean age of positively diagnosed cats at 9±0.3 years. Histopathological classification identified 20% of tumors as malignant, specifically squamous cell carcinoma, cribriform carcinoma, and comedocarcinoma. In conclusion, further epidemiological investigations are essential to understand the risk factors in the initiation and progression of these health issues. In contrast to canine species, FMTs are less diverse, predominantly simple malignant tumors. Benign FMTs are infrequent, and the existence of complex and mixed tumors in felines remains unclear. This study selected three FMT types for immunohistochemical analyses, revealing unusual histological characteristics. A set of three malignant tumors exhibited an epithelial/myoepithelial population, with consistent myoepithelial immunohistochemical signatures. All Grade I malignant tumors resulted in subjects surviving one-year post-diagnosis. Morphologically, we propose categorizing them as feline ductal/canalicular adenoma/carcinoma and feline intracanalicular papillary adenoma/carcinoma, respectively. These findings contribute novel insights to FMT classification and are valuable for prognostic studies.

Key words: mammary tumors, female cat, Northeast Algeria, histopathological investigation, immunohistochemical analysis

1. Bergman PJ. Mammary gland tumors. European veterinary conference. 2017:4.
2. Borrego JF, Cartagena JC, Engel J. Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002–2007). Vet Comp Onc. 2009; 7 (4): 213–221. DOI: 10.1111/j.1476-5829.2009.00194.x.
3. Brassart G. Les tumeurs mammaires chez la chienne: données bibliographiques récentes concernant l’approche diagnostique et la proposition d’un pronostic fiable. Thèse Méd. Vét. Lyon; 2008: 77. (in French)
4. Chahbouni Chahboni S. Molecular Classification of Breast Cancer. Doctoral Thesis in Medicine. Sidi Mohamed Ben Abdallah University, 2009.
5. Cloix C. La contraception chimique chez la chienne et la chatte: Réalisation d’une enquête sur les pratiques en clientèle vétérinaire. Thèse Méd. Vét. Lyon; 2011: 111. (in French)
6. David JLM. Etiopathogénie des tumeurs mammaires chez la chatte: actualisation des connaissances. Thèse de doctorat, 2010: 93. (in French)
7. Estrada M, Lagadic M. Tumeurs de la mamelle (Mammary tumors). In: Encyclopédie Vétérinaire. Paris; 2000: 2100: 1–7. (in French)
8. Fu DR, Kato D, Watabe A, Endo Y, Kadosawa T. Prognostic utility of apoptosis index, Ki-67 and survivin expression in dogs with nasal carcinoma treated with orthovoltage radiation therapy. J Vet Med Sci. 2014; 76 (11): 1505–1512. DOI: 10.1292/jvms.14-0245.
9. Geraldes M, Gärtner F, Schmitt F. Immunohistochemical study of hormonal receptors and cell proliferation in normal canine mammary glands and spontaneous mammary tumors. Vet Rec. 2000; 146: 403–406. DOI: 10.1136/vr.146.14.403.
10. Giménez F, Hecht S, Craig LE, Legendre AM. Early detection, aggressive therapy: optimizing the management of feline mammary masses. J Feline Med Surg. 2010; 12 (3): 214–224. DOI: 10.1016/j.jfms.2010.01.004.
11. Gogny A, Gogny M. Conduite thérapeutique devant des tumeurs mammaires chez le chien et le chat. Le Nouveau Praticien Vétérinaire Canine-Féline. 2009 ;9 (42): 43–49. (in French)
12. Grand JG, Gauthier O. Protocole opératoire d’exérèse des tumeurs mammaires. Chirurgie oncologique chez le chien et la chatte. Le Point Vétérinaire. 2006; 270. Available at: https://www.lepointveterinaire.fr/publications/le-point-veterinaire/article/n-270/protocole-operatoire-d-exerese-des-tumeurs-mahtml
13. Gross TL, Ihrke PJ, Walder EJ, Affolter VK. Lymphocytic tumors. In: Gross TL, Ihrke PJ, Walder EJ, Affolter VK (eds). Skin Diseases of the Dog and Cat: Clinical and Histopathologic Diagnosis. 2^nd Oxford, Blackwell, 2005: 866–893. DOI: 10.1002/9780470752487.ch37.
14. Helary J. Prévention et traitement des tumeurs mammaires chez la chienne et la chatte — Étude bibliographique. Thèse Méd. Vét. Nantes; 2006: 86. (in French)
15. Hughes K, Dobson JM. Prognostic histopathological and molecular markers in feline mammary neoplasia. Vet J. 2012; 194 (1): 19–26. DOI: 10.1016/j.tvjl.2012.05.008.
16. Ito T, Kadosawa T, Mochizuki M, Matsunaga S, Nishimura R, Sasaki N. Prognosis of malignant mammary tumor in 53 cats. J Vet Med Sci. 1996; 58 (8): 723–726. DOI: 10.1292/jvms.58.723.
17. Jensen MB, Lænkholm AV, Nielsen TO, Eriksen JO, Wehn P, Hood T, Ram N, Buckingham W, Ferree S, Ejlertsen B. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer Breast Cancer Res. 2018; 20: 79. DOI: 10.1186/s13058-018-1012-0.
18. Jurka P, Max A. Treatment of fibroadenomatosis in 14 cats with aglepristone — changes in blood parameters and follow-up. 2009; 165 (22): 657–660. DOI: 10.1136/vr.165.22.657.
19. Lana SE, Rutteman GR, Withrow SJ. Tumors of mammary gland. In: Withrow SJ, MacEwen EG (eds). Small Animal Clinical Oncology. 4^th St. Louis, Elsevier, 2007: 619–636. DOI: 10.1016/B978-072160558-6.50029-0.
20. Leidinger E, Hooijberg E, Sick K, Reinelt B, Kirtz G. Fibroepithelial hyperplasia in an entire male cat: cytologic and histopathological features. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2011; 39 (3): 198–202. DOI: 10.1055/s-0038-1623578.
21. Leydier E. Élaboration d’un site internet à destination des propriétaires de chiens et de chats atteints de cancers. Thèse Med. Vét, Campus vétérinaire de Lyon, 2018: 77. (in French)
22. Loukopoulos P, Sutton RH, Lynch P, Gee DC. Ectopic mammary carcinoma in a male cat. 2007; 160 (6): 203–204. DOI: 10.1136/vr.160.6.203-a.
23. Matos AJ, Baptista CS, Gärtner MF, Rutteman GR. Prognostic studies of canine and feline mammary tumours: the need for standardized procedures. Vet J. 2012; 193: 24–31. DOI: 10.1016/j.tvjl.2011.12.019.
24. Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, Ratto A, Sambucco PL, Sestito V, Tanara G, Bocchini V. Cancer incidence in pet dogs: findings of the animal tumor registry of Genoa, Italy. J Vet Intern Med. 2008; 22 (4): 976–984. DOI: 10.1111/j.1939-2008.0133.x.
25. Millanta F, Citi S, Della Santa D, Porciani M, Poli A. COX-2 expression in canine and feline invasive mammary carcinomas: Correlation with clinicopathological features and prognostic molecular markers. Breast Cancer Res Treat. 2006; 8: 115–120. DOI: 10.1007/s10549-005-9138-z.
26. Mills S, Musil KM, Davies LJ, Hendrick S, Duncan C, Jackson ML, Kidney B, Philibert H, Wobeser BK, Simko E. Mammary carcinoma: A retrospective survival analysis. Vet Pathol. 2015; 52 (2): 238–249. DOI: 10.1177/0300985814543198.
27. Misdorp W, Else R, Hellmen E. Histological classification of mammary tumors of the dog and the cat. Washington, DC, American Registry of Pathology; 1999.
28. Muraro L, White RS. Complications of ovariohysterectomy procedures performed in 1880 dogs. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2014; 42 (5): 297–302. DOI: 10.1055/s-0038-1623776.
29. Nelson RW, Guillermo C. Small Animal Internal Medicine. 3^rd Mosby; 2003: 884–885. ISBN 978-0323017244.
30. Peña L, Gama A, Goldschmidt MH, Abadie J, Benazzi C, Castagnaro M, Díez L, Gärtner F, Hellmén E, Kiupel M, Millán Y, Miller MA, Nguyen F, Poli A, Sarli G, Zappulli V, Martín de las Mulas J. Canine mammary tumours: A review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistry. Vet Pathol. 2014; 51 (1): 127–145. DOI: 10.1177/0300985813509388.
31. Viste JR, Myers SL, Singh B, Simko E. Feline mammary adenocarcinoma: tumor size as a prognostic indicator. Can Vet J. 2002; 43 (1): 33–37. PMID: 11802667.
32. Wypij J, Fan TM, Lorimier L. Malignant mammary tumors: Biologic behavior, prognostic factors, and therapeutic approach in cats. Vet Med. 2006; 101 (6): 352–366. Available ar: https://www.researchgate.net/publication/266141988
33. Zappulli V, Caliari D, Rasotto R, Ferro S, Castagnaro M, Goldschmidt M. Proposed classification of the feline “complex” mammary tumors as ductal and intraductal papillary mammary tumors. Vet Pathol. 2013; 50 (6): 1070–1077. DOI: 10.1177/0300985813488894.